Eloxx Pharmaceuticals, Inc.

Healthcare · Biotechnology · United States

Last price 13.2 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 53.28M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates that modulate the ribosome and promote readthrough of premature stop codons caused by nonsense mutations in the United States, Israel, and Australia. The company is developing exaluren, a eukaryotic ribosome-selective glycoside in a Phase 2 trial for the treatment of rare kidney diseases, including Alport syndrome with nonsense mutations, cystic fibrosis with nonsense mutations, and nephropathic cystinosis with nonsense mutations,...